デフォルト表紙
市場調査レポート
商品コード
1439652

経腸栄養剤 - 世界市場の考察、競合情勢、市場予測(2030年)

Enteral Feeding Formula - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円
経腸栄養剤 - 世界市場の考察、競合情勢、市場予測(2030年)
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の経腸栄養剤の市場規模は、2023年に67億6,000万米ドル、2030年までに72億3,000万米ドルに達し、2024年~2030年の予測期間にCAGRで1.13%の成長が見込まれます。市場は、さまざまな慢性疾患を発症しやすい老年人口の負担の増加、がん、脳卒中、慢性肝疾患、慢性閉塞性肺疾患(COPD)、糖尿病などの慢性疾患の有病率の上昇、未熟児出産の増加、経腸栄養に対する世界中での意識の高まりによって成長が見込まれています。また、製品分野における先進技術を利用したデバイスの開発への注力の積み重ねも、世界の経腸栄養剤市場に寄与している要因の1つです。

経腸栄養剤の市場力学

経腸栄養剤市場は、さまざまな理由によって製品需要が伸びており、その1つは、がん、脳卒中、慢性肝疾患、慢性閉塞性肺疾患(COPD)、糖尿病などの慢性疾患の高い有病率です。

WHO(2020)によると、世界の死因の第1位はがんで、2020年に約1,000万人が死亡しています。

さらに、Cancer Research UK(2018)によると、がんに罹患する人口は今後増加すると予測されています。彼らの2018年のレポートによると、主ながんの罹患率と人口増加の近年の動向が一致している場合、2040年までに世界中で毎年2,750万人の新たながん患者が発生すると予測されています。

世界保健機関(WHO)(2022)が発表したデータによると、心血管障害は毎年約1,790万人の命に影響を与える世界最大の死因と考えられています。さらに、2019年のWorld Heart Federationは、2030年までに2,300万人以上の命が心血管障害による影響を受けると推定していました。

したがって、世界中での慢性疾患の有病率の上昇により、経腸栄養剤の需要が増加すると予測されます。ICUの患者は経口摂取に抵抗があるため、経腸栄養剤で必要な栄養素を摂取することが求められます。

したがって、患者の適切な栄養補給を促進するために、経腸栄養剤の需要が増加しており、経腸栄養剤市場全体の成長につながっています。

経腸栄養剤の需要に影響を与えるもう1つの重要な特徴は、世界中での老年人口の増加です。世界保健機関(WHO)が提供したデータによると、2020年に世界中で約10億人が60歳以上になります。さらに、2050年までに60歳以上の老年人口は倍増し、約21億人に達すると予測され、80歳以上の老年人口は2020年~2050年に3倍の4億2,600万人に達すると推定されます。老年人口の増加は、世界中での経腸栄養の患者数の増加につながると予測され、それが予測期間の経腸栄養剤の需要の増加につながり、経腸栄養剤市場の成長を促進します。

COVID-19パンデミックの発生は世界中に大きな影響を与えました。パンデミック中、多くの患者が栄養補給のために家庭用の経腸栄養剤を必要としました。ICUにおける栄養に関するEuropean Society for Clinical Nutrition and Metabolism(ESPEN)のガイドラインによると、重度のCOVID-19患者には胃の経腸栄養が推奨されており、ICU入室後48時間以内に流量調整器付きポンプを使用して行うことが望ましいとされています。そのため、経腸栄養剤の需要が加速しました。COVID-19症例の増加により、世界的に経腸栄養剤への依存が高まっています。これが世界の経腸栄養剤市場の成長の加速につながっています。

しかし、一部の患者はアレルギー体質であり、これらの製剤の使用は重篤な経腸栄養関連の合併症リスクを伴うなど、特定の要因がさらなるリスクをもたらし、世界の経腸栄養剤市場の成長を抑制する可能性があります。

経腸栄養剤市場のセグメント分析

経腸栄養剤市場の栄養剤セグメントでは、標準製剤市場セグメントが大きなシェアを占める見込みです。

この製品セグメントの市場シェアが大きいのは、これらの製剤を採用する患者が増加しているためです。標準製剤は、適切な健康状態を維持するために必要なすべての必須栄養素で構成されています。

当レポートでは、世界の経腸栄養剤市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 経腸栄養剤市場レポートのイントロダクション

第2章 経腸栄養剤市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価
  • 財務ベンチマーク

第3章 規制と特許の分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 経腸栄養剤市場の主な要因の分析

  • 経腸栄養剤市場の促進要因
    • 老年人口の増加
    • 未熟児出産の増加
    • 技術の進歩
  • 経腸栄養ミルクの制約と課題
    • アレルギー反応
    • 重度の経腸栄養関連の合併症のリスク
  • 経腸栄養粉ミルクの機会
    • メーカー各社の戦略的事業活動の高まり
    • 新興市場をターゲットにした製品の発売

第5章 経腸栄養剤のポーターのファイブフォース分析

第6章 経腸栄養剤市場に対するCOVID-19の影響分析

第7章 経腸栄養剤市場のレイアウト

  • 栄養剤別
    • 標準製剤
    • 特定疾患向け製剤
    • その他
  • 患者タイプ別
    • 成人
    • 小児
  • 用途別
    • 腫瘍
    • 神経
    • 疼痛管理
    • 糖尿病
    • 栄養不足
  • エンドユーザー別
    • 病院
    • 在宅ケア
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 経腸栄養剤:世界の企業シェア分析 - 主要3~5社

第9章 経腸栄養剤の企業と製品のプロファイル

  • Fresenius Health Care Group
  • Mead Johnson & Company LLC
  • Victus, Inc.
  • Global Health Products, Inc.
  • Meiji Holdings Co., Ltd.
  • Ajinomoto Cambrooke, Inc.
  • B. Braun Melsungen AG
  • Baxter
  • Nestle S.A.
  • Laborie
  • Abbott
  • Dandle LION Medical
  • Prolacta Bioscience Inc.
  • Kate Farms
  • Nutricia (Danone S.A.)

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis on Enteral Feeding Formula Market
  • Table 3 Enteral Feeding Formula Market Analysis in Global (2021-2030)
  • Table 4 Enteral Feeding Formula Market Analysis in Global by Feeding Formula (2021-2030)
  • Table 5 Enteral Feeding Formula Market Analysis in Global by Patient Type (2021-2030)
  • Table 6 Enteral Feeding Formula Market Analysis in Global by Application (2021-2030)
  • Table 7 Enteral Feeding Formula Market Analysis in Global by End User (2021-2030)
  • Table 8 Enteral Feeding Formula Market Analysis in Global by Geography (2021-2030)
  • Table 9 Enteral Feeding Formula Market Analysis in North America (2021-2030)
  • Table 10 Enteral Feeding Formula Market Analysis in North America by Feeding Formula (2021-2030)
  • Table 11 Enteral Feeding Formula Market Analysis in North America by Patient Type (2021-2030)
  • Table 12 Enteral Feeding Formula Market Analysis in North America by Application (2021-2030)
  • Table 13 Enteral Feeding Formula Market Analysis in North America by End User (2021-2030)
  • Table 14 Enteral Feeding Formula Market Analysis in North America by Country (2021-2030)
  • Table 15 Enteral Feeding Formula Market Analysis in the US (2021-2030)
  • Table 16 Enteral Feeding Formula Market Analysis in Canada (2021-2030)
  • Table 17 Enteral Feeding Formula Market Analysis in Mexico (2021-2030)
  • Table 18 Enteral Feeding Formula Market Analysis in Europe (2021-2030)
  • Table 19 Enteral Feeding Formula Market Analysis in Europe by Feeding Formula (2021-2030)
  • Table 20 Enteral Feeding Formula Market Analysis in Europe by Patient Type (2021-2030)
  • Table 21 Enteral Feeding Formula Market Analysis in Europe by Application (2021-2030)
  • Table 22 Enteral Feeding Formula Market Analysis in Europe by End User (2021-2030)
  • Table 23 Enteral Feeding Formula Market Analysis in Europe by Country (2021-2030)
  • Table 24 Enteral Feeding Formula Market Analysis in France (2021-2030)
  • Table 25 Enteral Feeding Formula Market Analysis in Germany (2021-2030)
  • Table 26 Enteral Feeding Formula Market Analysis in UK (2021-2030)
  • Table 27 Enteral Feeding Formula Market Analysis in Italy (2021-2030)
  • Table 28 Enteral Feeding Formula Market Analysis in Spain (2021-2030)
  • Table 29 Enteral Feeding Formula Market Analysis in Russia (2021-2030)
  • Table 30 Enteral Feeding Formula Market Analysis in Rest of Europe (2021-2030)
  • Table 31 Enteral Feeding Formula Market Analysis in Asia Pacific (2021-2030)
  • Table 32 Enteral Feeding Formula Market Analysis in Asia Pacific by Feeding Formula (2021-2030)
  • Table 33 Enteral Feeding Formula Market Analysis in Asia Pacific by Patient Type (2021-2030)
  • Table 34 Enteral Feeding Formula Market Analysis in Asia Pacific by Application (2021-2030)
  • Table 35 Enteral Feeding Formula Market Analysis in Asia Pacific by End User (2021-2030)
  • Table 36 Enteral Feeding Formula Market Analysis in Asia Pacific by Country (2021-2030)
  • Table 37 Enteral Feeding Formula Market Analysis in China (2021-2030)
  • Table 38 Enteral Feeding Formula Market Analysis in Japan (2021-2030)
  • Table 39 Enteral Feeding Formula Market Analysis in India (2021-2030)
  • Table 40 Enteral Feeding Formula Market Analysis in Australia (2021-2030)
  • Table 41 Enteral Feeding Formula Market Analysis in South Korea (2021-2030)
  • Table 42 Enteral Feeding Formula Market Analysis in Rest of Asia Pacific (2021-2030)
  • Table 43 Enteral Feeding Formula Market Analysis in Rest of the World (2021-2030)
  • Table 44 Enteral Feeding Formula Market Analysis in Rest of the World by Feeding Formula (2021-2030)
  • Table 45 Enteral Feeding Formula Market Analysis in Rest of the World by Patient Type (2021-2030)
  • Table 46 Enteral Feeding Formula Market Analysis in Rest of the World by Application (2021-2030)
  • Table 47 Enteral Feeding Formula Market Analysis in Rest of the World by End User (2021-2030)
  • Table 48 Enteral Feeding Formula Market Analysis in Rest of the World by Country (2021-2030)
  • Table 49 Enteral Feeding Formula Market Analysis in Middle East (2021-2030)
  • Table 50 Enteral Feeding Formula Market Analysis in Africa (2021-2030)
  • Table 51 Enteral Feeding Formula Market Analysis in South America (2021-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis on Enteral Feeding Formula Market
  • Figure 3 Enteral Feeding Formula Market Analysis in Global (2021-2030)
  • Figure 4 Enteral Feeding Formula Market Analysis in Global by Feeding Formula (2021-2030)
  • Figure 5 Enteral Feeding Formula Market Analysis in Global by Patient Type (2021-2030)
  • Figure 6 Enteral Feeding Formula Market Analysis in Global by Application (2021-2030)
  • Figure 7 Enteral Feeding Formula Market Analysis in Global by End User (2021-2030)
  • Figure 8 Enteral Feeding Formula Market Analysis in Global by Geography (2021-2030)
  • Figure 9 Enteral Feeding Formula Market Analysis in North America (2021-2030)
  • Figure 10 Enteral Feeding Formula Market Analysis in North America by Feeding Formula (2021-2030)
  • Figure 11 Enteral Feeding Formula Market Analysis in North America by Patient Type (2021-2030)
  • Figure 12 Enteral Feeding Formula Market Analysis in North America by Application (2021-2030)
  • Figure 13 Enteral Feeding Formula Market Analysis in North America by End User (2021-2030)
  • Figure 14 Enteral Feeding Formula Market Analysis in North America by Country (2021-2030)
  • Figure 15 Enteral Feeding Formula Market Analysis in the US (2021-2030)
  • Figure 16 Enteral Feeding Formula Market Analysis in Canada (2021-2030)
  • Figure 17 Enteral Feeding Formula Market Analysis in Mexico (2021-2030)
  • Figure 18 Enteral Feeding Formula Market Analysis in Europe (2021-2030)
  • Figure 19 Enteral Feeding Formula Market Analysis in Europe by Feeding Formula (2021-2030)
  • Figure 20 Enteral Feeding Formula Market Analysis in Europe by Patient Type (2021-2030)
  • Figure 21 Enteral Feeding Formula Market Analysis in Europe by Application (2021-2030)
  • Figure 22 Enteral Feeding Formula Market Analysis in Europe by End User (2021-2030)
  • Figure 23 Enteral Feeding Formula Market Analysis in Europe by Country (2021-2030)
  • Figure 24 Enteral Feeding Formula Market Analysis in France (2021-2030)
  • Figure 25 Enteral Feeding Formula Market Analysis in Germany (2021-2030)
  • Figure 26 Enteral Feeding Formula Market Analysis in UK (2021-2030)
  • Figure 27 Enteral Feeding Formula Market Analysis in Italy (2021-2030)
  • Figure 28 Enteral Feeding Formula Market Analysis in Spain (2021-2030)
  • Figure 29 Enteral Feeding Formula Market Analysis in Russia (2021-2030)
  • Figure 30 Enteral Feeding Formula Market Analysis in Rest of Europe (2021-2030)
  • Figure 31 Enteral Feeding Formula Market Analysis in Asia Pacific (2021-2030)
  • Figure 32 Enteral Feeding Formula Market Analysis in Asia Pacific by Feeding Formula (2021-2030)
  • Figure 33 Enteral Feeding Formula Market Analysis in Asia Pacific by Patient Type (2021-2030)
  • Figure 34 Enteral Feeding Formula Market Analysis in Asia Pacific by Application (2021-2030)
  • Figure 35 Enteral Feeding Formula Market Analysis in Asia Pacific by End User (2021-2030)
  • Figure 36 Enteral Feeding Formula Market Analysis in Asia Pacific by Country (2021-2030)
  • Figure 37 Enteral Feeding Formula Market Analysis in China (2021-2030)
  • Figure 38 Enteral Feeding Formula Market Analysis in Japan (2021-2030)
  • Figure 39 Enteral Feeding Formula Market Analysis in India (2021-2030)
  • Figure 40 Enteral Feeding Formula Market Analysis in Australia (2021-2030)
  • Figure 41 Enteral Feeding Formula Market Analysis in South Korea (2021-2030)
  • Figure 42 Enteral Feeding Formula Market Analysis in Rest of Asia Pacific (2021-2030)
  • Figure 43 Enteral Feeding Formula Market Analysis in Rest of the World (2021-2030)
  • Figure 44 Enteral Feeding Formula Market Analysis in Rest of the World by Feeding Formula (2021-2030)
  • Figure 45 Enteral Feeding Formula Market Analysis in Rest of the World by Patient Type (2021-2030)
  • Figure 46 Enteral Feeding Formula Market Analysis in Rest of the World by Application (2021-2030)
  • Figure 47 Enteral Feeding Formula Market Analysis in Rest of the World by End User (2021-2030)
  • Figure 48 Enteral Feeding Formula Market Analysis in Rest of the World by Country (2021-2030)
  • Figure 49 Enteral Feeding Formula Market Analysis in Middle East (2021-2030)
  • Figure 50 Enteral Feeding Formula Market Analysis in Africa (2021-2030)
  • Figure 51 Enteral Feeding Formula Market Analysis in South America (2021-2030)
  • Figure 52 Market Drivers
  • Figure 53 Market Barriers
  • Figure 54 Market Opportunities
  • Figure 55 PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0491

Enteral Feeding Formula Market By Feeding Formula (Standard Formula, Disease-Specific Formula, Others), By Patient Type (Adults, Pediatrics), By Application (Oncology Neurology, Pain Management, Diabetes, Nutrition Deficiency, Others), By End-User (Hospitals, Homecare, Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to higher prevalence of chronic diseases and rising technological advancements in product development

Global Enteral Feeding Formula Market was valued at USD 6.76 billion in 2023, growing at a CAGR of 1.13% during the forecast period from 2024 to 2030, to reach USD 7.23 billion by 2030. The Enteral Feeding Formula market is expected to witness growth owing to the growing burden of the geriatric population who are susceptible to developing various chronic disorders, higher prevalence of chronic diseases such as cancer, stroke, chronic liver disease, Chronic Obstructive Pulmonary Disease (COPD), and diabetes; higher premature births, growing awareness of enteral nutrition across the globe. In addition, accumulative focus on developing technologically advanced devices in the product arena are some of the factors contributing to the Global Enteral Feeding Formula Market.

Enteral Feeding Formula Market Dynamics:

The Enteral Feeding Formula Market is witnessing a growth in product demand owing to various reasons, one of them being the higher prevalence of chronic diseases such as cancer, stroke, chronic liver disease, Chronic Obstructive Pulmonary Disease (COPD), and diabetes.

As per WHO 2020, the leading cause of death worldwide was cancer which accounted for nearly 10 million deaths in 2020.

Moreover, according to Cancer Research UK 2018, the population suffering from cancer is expected to increase in the future. As per their 2018 report, if recent trends in the incidence of major cancers and population growth are consistent, it is predicted that there will be 27.5 million new cancer cases worldwide each year by 2040.

As per the data provided by the World Health Organization 2022, cardiovascular disorders are considered the leading cause of death worldwide affecting about 17.9 million lives every year. Furthermore, the World Heart Federation in the year 2019 had estimated that more than 23 million lives will be affected owing to cardiovascular disorders by the year 2030.

Therefore, the rising prevalence of chronic disorders across the globe is further expected to aid in the increasing demand for Enteral Feeding Formula, as the patients in ICUs are not comfortable in taking food orally therefore it will become necessary to give the required nutrients through enteral feeding.

Therefore, in order to facilitate proper nutrition in patients, Enteral Feeding Formula is witnessing an increase in demand, leading to overall Enteral Feeding Formula market growth.

Another key aspect influencing the demand for Enteral Feeding Formula is the increasing geriatric population base across the globe. According to the data provided by the World Health Organization, in 2020, about one billion people across the world were over the age of 60. The source further stated that by 2050, the elderly population in the 60 and above age group is expected to double in number representing about 2.1 billion people, and people in the age group of 80 and above are estimated to triple between 2020 and 2050 reaching 426 million. The rising elderly population is expected to lead to the rise in the patient population of enteral feeding across the world, which in turn would lead to an increase in demand for Enteral Feeding Formula during the forecast period, which will drive the Enteral Feeding Formula market growth.

The outbreak of the COVID-19 pandemic had a profound impact across the globe. During the pandemic, many patients required a home Enteral Feeding Formula for the care of their nutritional requirements. According to the guidelines by the European Society for Clinical Nutrition and Metabolism (ESPEN) on nutrition in the ICU, Gastric Enteral Nutrition is advised for severe COVID-19 patients and should be preferably performed using a pump with a flow regulator, within 48 hours of admission to the ICU. Therefore, the demand for Enteral Feeding Formula was accelerated. The increasing number of COVID cases has led to the patient being dependent more on Enteral Feeding Formula, globally. This has led to accelerating the growth of the Global Enteral Feeding Formula market.

However, certain factors like some patients are allergic and the use of these formulas are associated with severe enteral feeding-related complications risks, resulting in additional risks that may restrict the growth of the Global Enteral Feeding Formula Market.

Enteral Feeding Formula Market Segment Analysis:

Enteral Feeding Formula Market by Feeding Formula (Standard Formula, Disease-Specific Formula, Others), by Patient Type (Adults, Pediatrics), by Application (Oncology, Neurology, Pain Management, Diabetes, Nutrition Deficiency, Others), by End-User (Hospitals, Homecare, Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).

Enteral Feeding Formula market Feeding Formula segment, the Standard Formula market segment will hold the major share of the Global Enteral Feeding Formula market.

The large market share of this product segment can be attributed to the growing patient adoption of these formulas. Standard Formula consists of all the essential nutrients required to maintain proper health conditions.

Some Standard Formulas can be used for both enteral feedings and as an oral supplement. They can also contain added ingredients, such as fiber, for digestive health and bowel management.

Moreover, the availability of a wide variety of options in the market coupled with rising demand for low-cost formulations being available for the end-users increases the acceptance of the Standard Formulas for enteral feeding for patients. Hence, all the above-mentioned factors are expected to drive the segment growth of the Enteral Feeding Formula market.

North America is expected to dominate the overall Global Enteral Feeding Formula Market:

North America is expected to dominate the overall Enteral Feeding Formula market during the forecast period. This domination is owing to the higher premature births, increasing geriatric population, technological advancements. Furthermore, high disposable income, sophisticated healthcare infrastructure, new product approvals, and increased awareness also propelled the market growth in this region.

As per the Centers for Disease Control and Prevention 2019, preterm birth affected 1 of every 10 infants born in the United States.

Additionally, according to the same statistics, in 2019, the rate of preterm birth among African-American women (14.4%) was about 50% higher than the rate of preterm birth among white or Hispanic women (9.3% and 10% respectively). Moreover, in 2018, preterm birth and low birth weight accounted for about 17% of infant deaths (deaths before 1 year of age). Thus, the burgeoning cases of premature births will contribute to the growth of the Enteral Feeding Formula Market in the region as the demand will increase.

Moreover, according to the data from the 2018 National Health Interview Survey (NHIS), more than half (51.8%) of adults had at least 1 of 10 selected diagnosed chronic conditions, and 27.2% of US adults had multiple chronic conditions.

As per the American Heart Association 2022, in the year 2019 cardiovascular disorders were the leading cause of death in the United States and coronary heart disease had accounted for about 42.1% of the deaths attributable to CVD in the United States.

Therefore, the rising adoption of the Enteral Feeding Formula in the country would result in the rising demand for treatments that make use of Enteral Feeding Formula, which in turn would provide a conducive growth environment for North America Enteral Feeding Formula market.

Furthermore, the increased emphasis on product development activities and the high interest of manufacturers in accessing local markets further aid in the growth of the regional markets for the Enteral Feeding Formula.

Therefore, the interplay of various factors such as the presence of a large patient population, encouraging reimbursement policies as well as new product launches in the region is expected to boost the North America Enteral Feeding Formula market during the forecast period.

Enteral Feeding Formula Market Key Players:

Some of the key market players operating in the Global Enteral Feeding Formula Market include Fresenius Health Care Group, Mead Johnson & Company LLC, Victus, Inc., Global Health Products, Inc., Meiji Holdings Co. Ltd., Ajinomoto Cambrooke Inc., B. Braun Melsungen AG, Baxter, Nestle S.A., Laborie, Abbott, Dandle LION Medical, Prolacta Bioscience Inc., Kate Farms, Nutricia (Danone S.A.), among others.

Recent Developmental Activities in the Enteral Feeding Formula Market:

On March 16, 2022, Kate Farms® announced its three newest products are eligible for insurance coverage for Medi-Cal beneficiaries effective January 1, 2022. The company's latest formula innovations - Kate Farms Pediatric Peptide 1.0 Vanilla and Kate Farms Standard 1.4 Vanilla and Plain - were listed in the approved Medi-Cal Rx List of Enteral Nutrition Products for children and adult recipients.

On Aug. 24, 2020, Kate Farms® announced the launch of two new organic, plant-based products - Kate Farms Standard 1.4 formula and Kate Farms Pediatric Peptide 1.0 formula.

On December 20, 2019, LABORIE Medical Technologies, announced the acquisition of Clinical Innovations for an enterprise value of USD 525 million. Clinical Innovations was a leading global provider of clinician-preferred medical devices for the labor & delivery (L&D) and neonatal intensive care unit (NICU) specialties and was actively involved in child nutrition.

Key Takeaways from the Enteral Feeding Formula Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Enteral Feeding Formula market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the Global Enteral Feeding Formula Market.

Various opportunities are available for the other competitor in the Enteral Feeding Formula Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Enteral Feeding Formula market growth in the coming future?

Target Audience who can be benefited from this Enteral Feeding Formula Market Report Study

Enteral Feeding Formula providers

Research organizations and consulting companies

Enteral Feeding Formula related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in Enteral Feeding Formula

Various End-users want to know more about the Enteral Feeding Formula Market and the latest technological developments in the Enteral Feeding Formula market.

Frequently Asked Questions for Enteral Feeding Formula Market:

1. What are Enteral Feeding Formulas?

Enteral Feeding formulas are used in patients that cannot swallow by mouth to provide nutritional supplementation. With the help of these formulas, food can be passed via the gastrointestinal tract. Enteral feeding is required in patients suffering from chronic conditions such as gastrointestinal disorders, cancer, and others.

2. What is the market for Global Enteral Feeding Formula?

Global Enteral Feeding Formula Market was valued at USD 6.76 billion in 2023, growing at a CAGR of 1.13% during the forecast period from 2024 to 2030, to reach USD 7.23 billion by 2030.

3. What are the drivers for the Global Enteral Feeding Formula?

The major drivers driving the demand for Enteral Feeding Formula are the growing burden of the geriatric population who are susceptible to developing various chronic disorders, higher prevalence of chronic diseases such as cancer, stroke, chronic liver disease, Chronic Obstructive Pulmonary Disease (COPD), and diabetes; higher premature births, growing awareness of enteral nutrition across the globe. In addition, accumulative focus on developing technologically advanced devices in the product arena are some of the factors contributing to the Global Enteral Feeding Formula Market.

4. Who are the key players operating in the Global Enteral Feeding Formula?

Some of the key market players operating in the Enteral Feeding Formula market include Fresenius Health Care Group, Mead Johnson & Company LLC, Victus, Inc., Global Health Products, Inc., Meiji Holdings Co. Ltd., Ajinomoto Cambrooke Inc., B. Braun Melsungen AG, Baxter, Nestle S.A., Laborie, Abbott, Dandle LION Medical, Prolacta Bioscience Inc., Kate Farms, Nutricia (Danone S.A.) and others.

5. Which regions has the highest share in the Enteral Feeding Formula market?

North America is expected to dominate the overall global Enteral Feeding Formula market during the forecast period from 2024 to 2030. This domination is owing to the higher premature births, increasing geriatric population, technological advancements. Furthermore, high disposable income, sophisticated healthcare infrastructure, new product approvals, and increased awareness also propelled the market growth in this region.

Table of Contents

1.Enteral Feeding Formula Market Report Introduction

2.Enteral Feeding Formula Market Executive summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Enteral Feeding Formula Market Key factors analysis

  • 4.1 Enteral Feeding Formula Market Drivers
    • 4.1.1 Increasing Geriatric Population
    • 4.1.2 The Higher Premature Births
    • 4.1.3 Rising Technological Advancements
  • 4.2 Enteral Feeding Formula Restraints and Challenges
    • 4.2.1 Allergic Reactions
    • 4.2.2 Severe Enteral Feeding-Related Complications Risks
  • 4.3 Enteral Feeding Formula Opportunities
    • 4.3.1 Rising Strategic Business Activities among the Manufacturers
    • 4.3.2 Targeting Emerging Markets for Product Launches

5. Enteral Feeding Formula Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Enteral Feeding Formula Market

7. Enteral Feeding Formula Market layout

  • 7.1 By Feeding Formula
    • 7.1.1 Standard Formula
    • 7.1.2 Disease-Specific Formula
    • 7.1.3 Others
  • 7.2 By Patient Type
    • 7.2.1 Adults
    • 7.2.2 Pediatrics
  • 7.3 By Application
    • 7.3.1 Oncology
    • 7.3.2 Neurology
    • 7.3.3 Pain Management
    • 7.3.4 Diabetes
    • 7.3.5 Nutrition Deficiency
    • 7.3.6 Others
  • 7.4 By End User
    • 7.4.1 Hospitals
    • 7.4.2 Homecare
    • 7.4.3 Others
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 North America Enteral Feeding Formula Market, by Feeding Formula
      • 7.5.1.2 North America Enteral Feeding Formula Market, by Patient Type
      • 7.5.1.3 North America Enteral Feeding Formula Market, by Application
      • 7.5.1.4 North America Enteral Feeding Formula Market, by End User
      • 7.5.1.5 North America Enteral Feeding Formula Market, by Country
      • 7.5.1.5.1 United States
      • 7.5.1.5.2 Canada
      • 7.5.1.5.3 Mexico
    • 7.5.2 Europe
      • 7.5.2.1 Europe Enteral Feeding Formula Market, by Feeding Formula
      • 7.5.2.2 Europe Enteral Feeding Formula Market, by Patient Type
      • 7.5.2.3 Europe Enteral Feeding Formula Market, by Application
      • 7.5.2.4 Europe Enteral Feeding Formula Market, by End User
      • 7.5.2.5 Europe Enteral Feeding Formula Market, by Country
      • 7.5.2.5.1 France
      • 7.5.2.5.2 Germany
      • 7.5.2.5.3 United Kingdom
      • 7.5.2.5.4 Italy
      • 7.5.2.5.5 Spain
      • 7.5.2.5.6 Russia
      • 7.5.2.5.7 Rest of Europe
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 Asia-Pacific Enteral Feeding Formula Market, by Feeding Formula
      • 7.5.3.2 Asia-Pacific Enteral Feeding Formula Market, by Patient Type
      • 7.5.3.3 Asia-Pacific Enteral Feeding Formula Market, by Application
      • 7.5.3.4 Asia-Pacific Enteral Feeding Formula Market, by End User
      • 7.5.3.5 Asia-Pacific Enteral Feeding Formula Market, by Country
      • 7.5.3.5.1 China
      • 7.5.3.5.2 Japan
      • 7.5.3.5.3 India
      • 7.5.3.5.4 Australia
      • 7.5.3.5.5 South Korea
      • 7.5.3.5.6 Rest of Asia Pacific
    • 7.5.4 Rest of the World (RoW)
      • 7.5.4.1 RoW Enteral Feeding Formula Market, by Feeding Formula
      • 7.5.4.2 RoW Enteral Feeding Formula Market, by Patient Type
      • 7.5.4.3 RoW Enteral Feeding Formula Market, by Application
      • 7.5.4.4 RoW Enteral Feeding Formula Market, by End User
      • 7.5.4.5 RoW Enteral Feeding Formula Market, by Region
      • 7.5.4.5.1 Middle East
      • 7.5.4.5.2 Africa
      • 7.5.4.5.3 South America

8. Enteral Feeding Formula Global Company Share Analysis - Key 3-5 Companies

9. Enteral Feeding Formula Company and Product Profiles

  • 9.1 Fresenius Health Care Group
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4 Product Listing
    • 9.1.5. Entropy
  • 9.2 Mead Johnson & Company LLC
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4 Product Listing
    • 9.2.5. Entropy
  • 9.3 Victus, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4 Product Listing
    • 9.3.5. Entropy
  • 9.4 Global Health Products, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4 Product Listing
    • 9.4.5. Entropy
  • 9.5 Meiji Holdings Co., Ltd.
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4 Product Listing
    • 9.5.5. Entropy
  • 9.6 Ajinomoto Cambrooke, Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4 Product Listing
    • 9.6.5. Entropy
  • 9.7 B. Braun Melsungen AG
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4 Product Listing
    • 9.7.5. Entropy
  • 9.8 Baxter
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4 Product Listing
    • 9.8.5. Entropy
  • 9.9 Nestle S.A.
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4 Product Listing
    • 9.9.5. Entropy
  • 9.10 Laborie
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5. Entropy
  • 9.11 Abbott
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4 Product Listing
    • 9.11.5. Entropy
  • 9.12 Dandle LION Medical
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4 Product Listing
    • 9.12.5. Entropy
  • 9.13 Prolacta Bioscience Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4 Product Listing
    • 9.13.5. Entropy
  • 9.14 Kate Farms
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4 Product Listing
    • 9.14.5. Entropy
  • 9.15 Nutricia (Danone S.A.)
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4 Product Listing
    • 9.15.5. Entropy

10. KOL Views

11. PROJECT APPROACH

12. About DelveInsight

13. Disclaimer & Contact Us